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In this pilot study, the acceptability of approaching 111 newly diagnosed colorectal cancer patients with the offer of genetic testing for
hereditary nonpolyposis colorectal cancer (HNPCC) was assessed. A total of 78% of participants found it highly acceptable to have
the information about HNPCC brought to their attention at that time.
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Although most cases of colorectal cancer occur sporadically, a
small proportion are due to known hereditary syndromes where
the onset of disease is at an earlier age. The commonest of these is
hereditary nonpolyposis colorectal cancer (HNPCC), an autosomal
dominant syndrome resulting from mutations in mismatch repair
(MMR) genes, which accounts for less than 1% of all colorectal
cancers (Evans et al, 1997). It has been estimated that male carriers
of an MMR mutation have a 74% lifetime risk of developing
colorectal cancer compared to 30% in females, who also have a
42% risk of endometrial cancer (Dunlop et al, 1997).
The Colorectal Cancer Genetic Susceptibility (COGS) study aims
to evaluate a new Scottish-wide research strategy for identifying
individuals at high risk of developing HNPCC. Newly diagnosed
colorectal cancer patients under the age of 55 years are offered
genetic testing for three mutations in MMR genes (i.e. MLH1,
MSH2, MSH6). This allows the identification of HNPCC families
and enables appropriate screening to be offered to asymptomatic
relatives at increased risk of the disease and to index cases
postsurgery.
Although a number of studies have investigated the psychosocial
aspects of genetic testing for HNPCC in colorectal cancer patients
(Vernon et al, 1997; Gritz et al, 1999; Kinney et al, 2000; Esplen
et al, 2001; Keller et al, 2002; Hadley et al, 2003), little is known
about the acceptability of approaching newly diagnosed colorectal
cancer patients with the offer of genetic testing.
This paper reports descriptive results of the pilot phase of a
patient feedback study. This study was an integral part of the
COGS study aiming to determine whether it was acceptable to
approach recently diagnosed colorectal cancer patients about
genetic testing at a time when they were already adjusting to a new
diagnosis.
MATERIALS AND METHODS
Participants
Ethical approval for the COGS study was obtained from the
multicentre research ethics committee. Eligible patients in Lothian
and Greater Glasgow who were approached for the COGS study
(with the permission of their health-care professional), were
invited to participate in the patient feedback study regardless of
whether they decided to participate in the COGS study but
provided that they:
1. had received a home visit from their local study recruitment
nurse.
2. were willing to be contacted to discuss the reasons for their
decision to/not to participate in the COGS study.
Procedure
Patients were invited to participate in the COGS study (pre- or
postoperatively) by their specialist nurse or by post. All patients
expressing interest were visited in their own home by the local
study recruitment nurse to: discuss the COGS study; provide
genetic counselling by constructing a detailed pedigree and
producing an estimated risk of HNPCC for their relatives (low/
moderate/high) based on Scottish guidelines (Haites et al, 2000);
gain written consent; take a blood sample for genetic testing. At the
end of the visit, all patients meeting the patient feedback study
criteria were given an information sheet about the study and a
feedback questionnaire, which they were asked to return in the
freepost envelope provided.
Measures
Participants’ age, gender and the risk of HNPCC to their relatives
were derived from clinical records.
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specific items (with multiple choice or Likert scale responses) to
assess:
1. Sociodemographic characteristics (i.e. marital status, educa-
tion, number of children).
2. Prior awareness of familial cancer risk.
3. Acceptability of approach with genetic information.
4. Decision-making factors concerning the genetic test.
5. Subjective understanding of issues discussed in genetic
counselling.
6. Expectation of the genetic test result.
7. Cancer and genetics worry.
RESULTS
A total of 160 patients, who were approached to participate in the
COGS study between February 1999 and July 2000, were eligible to
participate in the patient feedback study. Of the 160 questionnaires
given to patients, 111 (69%) were returned completed. Only one of
the 111 patients who completed the questionnaire had declined to
participate in the COGS study.
Of the 111 participants, 61 (55%) were male and 50 (45%) were
female ranging in age from 31 to 55 years (mean¼48.6, s.d.¼5.5).
The risk of HNPCC for their relatives was low for 60% of
participants (n¼65), moderate for 39% (n¼42) and high for 2%
(n¼2). The majority were married or living with a partner (n¼90,
83%), and had been educated up to age 16 years only (n¼56,
60%). In all, 81% (n¼89) had at least one child.
Most participants (n¼61, 58%) had no prior awareness that
colorectal cancer could run in families. A total of 36% (n¼37) had
been concerned that colorectal cancer might run in their family. Of
the 31% (n¼33) who had any experience of colorectal cancer in a
relative, 50% (n¼15) had been aware that colorectal cancer could
run in families and 69% (n¼20) had been concerned about this.
In all, 78% (n¼87) thought it was definitely acceptable to have
this genetic information brought to their attention at that time and
the remainder (n¼24, 22%) did not mind being approached with
the information.
After receiving the information sheet about the COGS study, but
prior to discussing participation with a member of staff, 91%
(n¼101) reported that they had decided to take the genetic test,
one individual (1%) had decided not to take the test and nine (8%)
were undecided.
Table 1 shows how participants rated the importance of several
factors in their decision whether to undergo genetic testing. For all
participants (except those without children), the decision-making
factor most frequently rated as very important was ‘to learn about
their children’s risk of developing colorectal cancer’.
Participants’ subjective understanding of issues discussed in
genetic counselling is presented in Table 2. The vast majority of
participants felt that they had understood these issues.
A minority of participants (n¼8, 7%) expected that they would
receive a positive test result (i.e. they would carry the genetic
mutation), 21% (n¼23) expected to test negative and 72%
(n¼79) were unsure.
Most participants (n¼97, 87%) reported some degree of
difficulty (a little, quite, very) coming to terms with the diagnosis
of cancer, with 15% (n¼17) overall reporting that it had been very
difficult. Similarly, the majority of participants (n¼89, 80%)
indicated that it had been difficult to cope physically with their
illness and treatment, with eight participants (7%) overall
reporting that it had been very difficult. A total of 45% of
participants (n¼48) rated their current worry about their cancer
and its treatment at or above the midpoint of 4 on a 1 (not at all) to
7 (all the time) scale.
In total, 19% of participants (n¼21) rated their current level of
worry caused by the genetics information at or above the midpoint
of 4 on a 1 (not at all) to 7 (all the time) scale. Of these 21
participants, 80% (n¼16) had rated their current worry about
their cancer and its treatment at or above the midpoint, 57%
(n¼12) and 43% (n¼9) had been informed that their relatives
were at low or moderate risk of HNPCC, respectively.
DISCUSSION
The majority of participants found it highly acceptable to have
information about HNPCC brought to their attention at a time
when they were coping with a new diagnosis of colorectal cancer,
despite a lack of prior awareness that the disease could run in
families. The vast majority had decided to accept the offer of a
genetic test and reported high levels of subjective understanding
concerning genetic testing. Similar findings have been reported in
American colorectal cancer patients in terms of positive attitudes
to undergoing HNPCC genetic testing (Gritz et al, 1999).
The results suggest that although receiving information about
HNPCC did not cause most participants undue worry, a minority
of participants rated this worry at the top end of the scale. This was
despite the fact that most had been informed that their relatives
were at low risk of HNPCC. Likewise, these participants tended to
Table 1 Importance of several factors in participants’ decision-making
about genetic testing
a
Frequency of ratings on level of
importance
Decision-making factor Very Somewhat Not
Potential advantages
To learn about children’s risk
b 87 (97%) 2 (2%) 1 (1%)
To help research 99 (89%) 10 (9%) 2 (2%)
Access to screening for family 94 (85%) 14 (13%) 3 (3%)
To inform follow-up care 90 (82%) 15 (14%) 5 (5%)
To learn more about own cancer 80 (73%) 23 (21%) 7 (6%)
To be reassured 74 (67%) 30 (27%) 7 (6%)
To plan for the future 70 (63%) 31 (28%) 10 (9%)
Potential disadvantages
Concern about effect on family 95 (86%) 14 (13%) 2 (2%)
Concern that result not accurate 37 (34%) 36 (33%) 37 (34%)
Concern about causing
problems, for example, insurance
31 (29%) 42 (39%) 36 (33%)
Concern with getting upset 29 (26%) 35 (32%) 46 (42%)
aSample size varies due to missing data.
bNot applicable for the 21 participants who
did not have children.
Table 2 Subjective understanding of issues discussed in genetic
counselling
a
Frequency of ratings on
understanding
Issue discussed in genetic
counselling Understand Not sure
Why you have been offered the blood test? 111 (100%) 0
What the blood test is for? 109 (100%) 0
What a positive result would mean for you? 98 (92%) 9 (8%)
What a negative result would mean for
you?
102 (95%) 5 (5%)
What a positive result would mean for your
family?
100 (93%) 8 (7%)
What a negative result would mean for
your family?
98 (93%) 8 (8%)
aSample size varies due to missing data.
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end of the scale. Further research is needed using standardised
measures of psychological distress to assess the clinical signifi-
cance of this finding among patients who may already be
experiencing high levels of distress as a consequence of their
recent diagnosis of cancer. This would enable appropriate
psychological treatment to be offered to clinically distressed
patients and interventions to be targeted at those patients who are
likely to become distressed as a result of receiving information
about HNPCC. The results of earlier studies of colorectal cancer
patients undergoing genetic testing suggested that 17% (Gritz et al,
1999) to 24% (Vernon et al, 1997) were suffering from clinically
significant levels of depression.
Further research is warranted to: investigate the reasons for
nonparticipation in a study offering colorectal cancer patients
genetic testing for HNPCC; identify characteristics that may
help to explain why some patients are less likely to participate in
this type of study; establish whether subjectively reported under-
standing of genetic testing can be objectively verified; assess the
longer-term psychological consequences of this novel screening
strategy.
Results from this pilot study will direct the assessment of a
larger cohort of colorectal cancer patients invited to participate in
the COGS study. The results of this subsequent research could help
to determine whether this novel screening strategy has the
potential to be incorporated into future NHS services for colorectal
cancer patients.
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